506019685 04/17/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6066398

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
INTERFACE BIOLOGICS INC.	04/16/2020

RECEIVING PARTY DATA

Name:	RIPPLE THERAPEUTICS CORPORATION	
Street Address:	MARS CENTER, SOUTH TOWER	
Internal Address:	101 COLLEGE STREET, SUITE 300	
City:	TORONTO	
State/Country:	CANADA	
Postal Code:	M5G 1L7	

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	16798219	

CORRESPONDENCE DATA

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6504939300

Email: PATENTDOCKET@WSGR.COM, GMETCALF@WSGR.COM

Correspondent Name: WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	58135-701.201	
NAME OF SUBMITTER:	GISELE METCALF	
SIGNATURE:	/Gisele Metcalf/	
DATE SIGNED:	04/17/2020	

Total Attachments: 1

source=58135_701_201 Assignment IBI to Ripple#page1.tif

PATENT 506019685 REEL: 052426 FRAME: 0656

CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 58135-701.201

WHEREAS, <u>Interface Biologics Inc.</u> (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

INTRAVITREAL INJECTOR

for which application serial number 16/798,219 was filed on February 21, 2020, in the United States Patent and Trademark Office;

WHEREAS, Ripple Therapeutics Corporation, a corporation incorporated under the laws of Canada, having a place of business at MaRS Center, South Tower, 101 College Street, Suite 300, Toronto, ON, M5G 1L7, Canada, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration, including at least \$1.00, acknowledged by said Assignor to have been received in full from said Assignee:

- 1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).
- 2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.
- 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.
- 4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 6. This instrument will be interpreted and construed in accordance with the laws of the Province of Ontario, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

Date: April 16th, 2020	ASSIC	GNOR - INTERFACE BIOLOGICS INC.			
	_ ,.	Name: Thomas Reeves Title: President & CEO			
RECEIVED AND AGREED TO BY ASSIGNEE: - RIPPLE THERAPEUTICS CORPORATION					
Date: April 16th, 2020	By:	1h-12			
	-	Name: Thomas Reeves Title: President and CEO			

58135-701.201 IBI to Ripple Assignment(11422254.1).doc

RECORDED: 04/17/2020

Page 1 of 1

PATENT REEL: 052426 FRAME: 0657